FDA clinical hold

Class actions filed against $PYPL over false revenue projections and $RGENX after FDA clinical hold on gene therapy following safety concerns.

Class action lawsuits filed against PayPal for misleading revenue projections and REGENXBIO for concealing gene therapy safety concerns, both triggering significant stock declines.

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

REGENXBIO faces class action lawsuit alleging securities violations over failure to disclose adverse information about RGX-111 before FDA clinical hold.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.